Statute Details
- Title: Health Products (Clinical Trials) Regulations 2016
- Act Code: HPA2007-S331-2016
- Type: Subsidiary legislation (sl)
- Enacting Act: Health Products Act (Cap. 122D), made under section 72
- Regulator: Health Sciences Authority (HSA), with Minister for Health approval
- Commencement: 1 November 2016
- Current status (as provided): Current version as at 27 March 2026
- Key structure: Part 1 (General); Part 2 (Clinical trials of therapeutic products or applicable CTGT products); Part 3 (Miscellaneous); Part 4 (Offences); Part 5 (Application to pending clinical trials)
- Key provisions (from extract): Definitions (reg. 2); Scope (reg. 3); Authorisation/notification (regs. 7–12); Good clinical practice and conduct (regs. 13–15); Consent (regs. 16–20); Safety measures and trial suspension/termination (regs. 21–22); Records and traceability (regs. 23–23A); Vigilance reporting (regs. 24–25); Labelling (reg. 26); Confidentiality and publication (regs. 27–28); Offences (reg. 29); Pending trials (reg. 30)
- Notable related instruments (as provided): Health Products Act; Healthcare Services Act 2020; Human Biomedical Research Act 2015; Medical Registration Act 1997; Dental Registration Act 1999; Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
What Is This Legislation About?
The Health Products (Clinical Trials) Regulations 2016 (“CT Regulations”) set out the regulatory framework for conducting clinical trials in Singapore involving therapeutic products and certain cell, tissue and gene therapy products (CTGT products). In practical terms, the Regulations require sponsors and investigators to obtain the appropriate regulatory permission (authorisation or notification, depending on the trial category) and to comply with detailed obligations on trial conduct, subject consent, safety reporting, record-keeping, labelling, and confidentiality.
The Regulations are designed to protect research subjects and to ensure that clinical trials are conducted to acceptable scientific and ethical standards. They also support regulatory oversight by requiring timely reporting of serious adverse events, unexpected serious adverse drug reactions, and urgent safety measures. This enables the Health Sciences Authority (HSA) to monitor risk and intervene when necessary.
Although clinical research is often associated with the Human Biomedical Research Act 2015, the CT Regulations focus specifically on “health products” used as investigational products in clinical trials. The scope is therefore product- and trial-type driven. The Regulations also address special situations, including emergency clinical trials where standard consent processes may not be feasible.
What Are the Key Provisions?
1. Scope and definitions (Regs. 2–3). The Regulations begin with definitions that shape how obligations apply. For example, they define core concepts such as “adverse event” and “adverse drug reaction”, and they distinguish between an “investigational product” and an “auxiliary product”. They also define “clinical trial in an emergency situation”, which is critical for the consent regime in emergency settings. The scope provision (reg. 3) provides that the Regulations apply to clinical trials of specified products that are not observational. This means that not every study involving humans is automatically covered; the product category and trial type matter.
2. Sponsors, investigators, and trial documentation (Regs. 4–6). The Regulations allocate responsibilities to the “sponsor” and the “principal investigator” (and related roles). Sponsors are central to regulatory submissions and compliance management, while investigators are responsible for day-to-day trial conduct and subject-related duties. The Regulations also require an “investigator’s brochure” (reg. 6), which is a structured compilation of relevant clinical and non-clinical information about the investigational product. In practice, this brochure supports informed decision-making by investigators and underpins safety and protocol compliance.
3. Authorisation vs notification; amendments; urgent safety measures (Regs. 7–12). A major operational feature is the regulatory pathway. Regulation 7 sets out the requirement for authorisation for, or notification of, a clinical trial. Regulation 8 deals with applications for authorisation, while regulation 9 addresses notification. Regulation 10 governs amendments and “substantial amendments” to clinical trials, signalling that changes to protocol or trial particulars may require additional regulatory engagement. Regulation 11 requires notification of serious breaches and urgent safety measures—reflecting that compliance failures and safety risks must be escalated promptly. Regulation 12 requires notification of the status of the clinical trial, supporting ongoing oversight.
4. Good clinical practice and trial conduct (Regs. 13–15). The Regulations incorporate “good clinical practice” (GCP) as a baseline standard. Regulation 13 requires that clinical trials be conducted in accordance with GCP principles. Regulation 14 requires conduct in accordance with authorisations and notifications—meaning that regulatory permission is not merely procedural; it is binding on how the trial is run. Regulation 15 addresses the “place of clinical trial”, which is important for ensuring that trial sites meet the necessary conditions for safe and compliant conduct.
5. Consent and information duties, including emergency consent (Regs. 16–20). Subject consent is one of the most legally sensitive areas. Regulation 16 sets out requirements for consent of subjects (and related persons, where relevant). Regulation 17 provides a special consent pathway for emergency situations, where the subject cannot consent and legal representatives cannot be reached within the window period. Regulation 18 sets general requirements as to consent, while regulation 19 imposes a duty to give full explanation and information—ensuring that subjects understand the nature of the trial, risks, and relevant alternatives. Regulation 20 prohibits coercion, reinforcing that consent must be voluntary.
6. Safety of subjects: urgent safety measures, suspension, and termination (Regs. 21–22). The Regulations require prompt action when safety concerns arise. Regulation 21 addresses “urgent safety measures”, requiring the sponsor and/or investigators to implement and notify measures to protect subjects. Regulation 22 provides for suspension or termination of a clinical trial. This is a key enforcement lever: if risks outweigh benefits or if compliance failures occur, the trial may need to be stopped to prevent harm.
7. Records, traceability, and vigilance reporting (Regs. 23–25). Regulation 23 requires a record of clinical trials. This is essential for auditability and for demonstrating compliance with protocol and regulatory conditions. Regulation 23A adds traceability requirements for applicable CTGT products used in clinical trials, reflecting the higher complexity and risk profile of cell, tissue and gene therapies. For safety reporting, regulation 24 requires notifications of serious adverse events, and regulation 25 requires notifications of unexpected serious adverse drug reactions. These provisions ensure that safety signals are communicated to HSA in a timely manner.
8. Labelling (Reg. 26) and schedules. Labelling obligations are addressed in regulation 26, covering both investigational product and auxiliary product labelling. The Second Schedule sets out labelling requirements. In practice, correct labelling supports safe administration, prevents mix-ups, and provides essential information for investigators and dispensing staff.
9. Confidentiality, publication, and offences (Regs. 27–29). Regulation 27 protects confidential information, which is important for sponsor proprietary data and subject privacy. Regulation 28 addresses publication of information on clinical trials, supporting transparency. Regulation 29 sets out offences, providing the enforcement mechanism for breaches of the Regulations.
10. Pending clinical trials (Reg. 30). Regulation 30 addresses how the Regulations apply to clinical trials already pending at the time of relevant changes. This is crucial for sponsors managing ongoing studies during amendments to the regulatory framework.
How Is This Legislation Structured?
The CT Regulations are organised into five parts:
Part 1 (General) contains the citation and commencement (reg. 1), definitions (reg. 2), and the scope of application (reg. 3). This part establishes the interpretive foundation for the rest of the Regulations.
Part 2 (Clinical trials of therapeutic products or applicable CTGT products) is the core operational section. It is divided into: Division 1 (Sponsors; principal investigator; investigator’s brochure); Division 2 (regulatory submissions—authorisation/notification, amendments, serious breaches, urgent safety measures, and trial status); Division 3 (general duties—GCP and conduct; consent and information; safety and subject interests; records and traceability); Division 4 (vigilance—serious adverse events and unexpected serious adverse drug reactions); and Division 5 (labelling).
Part 3 (Miscellaneous) covers confidentiality and publication of information.
Part 4 (Offences) sets out criminal or regulatory offences for contraventions.
Part 5 (Application to pending clinical trials) provides transitional rules for trials already underway.
Two schedules supplement the Regulations: the First Schedule sets out “Principles of good clinical practice”, and the Second Schedule sets out Labelling requirements.
Who Does This Legislation Apply To?
The Regulations apply to clinical trials in Singapore involving specified health products used as investigational products, provided the trials are not observational. The key regulated actors are sponsors and investigators (including principal investigators and other relevant trial personnel), as well as trial sites and healthcare service providers where the trial is conducted.
Because the Regulations incorporate definitions tied to product categories (including CTGT products treated as a particular class under the CTGT Regulations), the applicability can depend on the nature of the investigational product and the trial design. Where a trial involves emergency circumstances, the emergency consent provisions apply only if the statutory conditions are met (life-threatening situation, inability to consent, and infeasibility of obtaining consents from legal representatives within the window period).
Why Is This Legislation Important?
For practitioners, the CT Regulations are significant because they translate ethical and scientific expectations into enforceable legal duties. Compliance is not limited to obtaining initial regulatory permission; sponsors must manage ongoing obligations across the trial lifecycle—protocol amendments, safety reporting, record-keeping, and labelling.
The Regulations also create a structured safety reporting regime. Serious adverse events and unexpected serious adverse drug reactions must be notified, and urgent safety measures must be communicated. This supports regulatory risk management and provides a basis for potential suspension or termination of trials. In litigation or regulatory investigations, these reporting and documentation duties often become central evidence of whether subjects were adequately protected.
Finally, the consent provisions—particularly the emergency consent framework—are legally critical. Practitioners advising sponsors, investigators, or healthcare institutions must ensure that consent processes comply with the Regulations and that emergency exceptions are used only when the statutory criteria are satisfied. Misuse of emergency consent can expose parties to enforcement risk under the offences provision.
Related Legislation
- Health Products Act (Cap. 122D)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Medical Registration Act 1997
- Dental Registration Act 1999
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
Source Documents
This article provides an overview of the Health Products (Clinical Trials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.